Cancer metabolism and drug resistance

Metabolites

Volumn 5, Issue 4, 2015, Pages 571-600

  Rahman, Mahbuba ^a   Hasan, Mohammad Rubayet ^a,b  

^a SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^b WEILL CORNELL MEDICAL COLLEGE   (Qatar)

Author keywords

Antimetabolites; Drug resistance; Metabolic flux analysis; Metabolic pathways; Systems biology; Targeted therapy

Indexed keywords

6 PHOSPHOFRUCTO 2 KINASE; 6 PHOSPHOFRUCTOKINASE; AMINO ACID TRANSPORTER; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FUMARATE HYDRATASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 4; HEXOKINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOCITRATE DEHYDROGENASE; LACTATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; PYRUVATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE KINASE; PYRUVATE KINASE; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN RECEPTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; SUCCINATE DEHYDROGENASE; TRANSKETOLASE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; CITRIC ACID CYCLE; DNA SEQUENCE; DRUG RESISTANCE; GENETIC ASSOCIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SEQUENCING; HUMAN; METABOLIC FLUX ANALYSIS; METABOLOMICS; NEOPLASM; NUCLEAR REPROGRAMMING; OXIDATIVE PHOSPHORYLATION; PENTOSE PHOSPHATE CYCLE; POSITRON EMISSION TOMOGRAPHY; REVIEW; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 85006201112     PISSN: None     EISSN: 22181989     Source Type: Journal    
DOI: 10.3390/metabo5040571     Document Type: Review

References (95)

1. Luengo-Fernandez, R.; Leal, J.; Gray, A.; Sullivan, R. Economic burden of cancer across the european union: A population-based cost analysis. Lancet Oncol. 2013, 14, 1165–1174.
2. Henderson, D.; Ogilvie, L.A.; Hoyle, N.; Keilholz, U.; Lange, B.; Lehrach, H.; Onco Track, C. Personalized medicine approaches for colon cancer driven by genomics and systems biology: Oncotrack. Biotechnol. J. 2014, 9, 1104–1114.
3. IARC. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available online: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (accessed on 21 September 2015).
4. Liu, H.; Lv, L.; Yang, K. Chemotherapy targeting cancer stem cells. Am. J. Cancer Res. 2015, 5, 880–893.
5. De Souza, R.; Zahedi, P.; Badame, R.M.; Allen, C.; Piquette-Miller, M. Chemotherapy dosing schedule influences drug resistance development in ovarian cancer. Mol. Cancer Ther. 2011, 10, 1289–1299.
6. Persidis, A. Cancer multidrug resistance. Nat. Biotechnol. 1999, 17, 94–95.
7. Crawford, S. Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. Front. Pharmacol. 2013, 4, 68, doi:10.3389/fphar.2013.00068.
8. Cimino, G.D.; Pan, C.X.; Henderson, P.T. Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer. Bioanalysis 2013, 5, 369–391.
9. Joo, W.D.; Visintin, I.; Mor, G. Targeted cancer therapy—Are the days of systemic chemotherapy numbered? Maturitas 2013, 76, 308–314.
10. Kroemer, G.; Pouyssegur, J. Tumor cell metabolism: Cancer’s achilles’ heel. Cancer Cell 2008, 13, 472–482.
11. Duckwall, C.S.; Murphy, T.A.; Young, J.D. Mapping cancer cell metabolism with(13)c flux analysis: Recent progress and future challenges. J. Carcinog. 2013, 12, 13, doi:10.4103/1477-3163.115422.
12. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674.
13. Johnson, C.; Warmoes, M.O.; Shen, X.; Locasale, J.W. Epigenetics and cancer metabolism. Cancer Lett. 2015, 356, 309–314.
14. Goncalves, E.; Bucher, J.; Ryll, A.; Niklas, J.; Mauch, K.; Klamt, S.; Rocha, M.; Saez-Rodriguez, J. Bridging the layers: Towards integration of signal transduction, regulation and metabolism into mathematical models. Mol. Biosyst. 2013, 9, 1576–1583.
15. Oliveira, A.P.; Jewett, M.C.; Nielsen, J. From Gene Expression to Metabolic Fluxes. In Introduction to Systems Biology; Choi, S., Ed.; The Humana Press Inc.: Totowa, NJ, USA, 2007.
16. Ward, P.S.; Thompson, C.B. Metabolic reprogramming: A cancer hallmark even warburg did not anticipate. Cancer Cell 2012, 21, 297–308.
17. Koppenol, W.H.; Bounds, P.L.; Dang, C.V. Otto warburg’s contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 2011, 11, 325–337.
18. Mardis, E.R.; Wilson, R.K. Cancer genome sequencing: A review. Hum. Mol. Genet. 2009, 18, R163–R168.
19. Kitano, H. Systems biology: A brief overview. Science 2002, 295, 1662–1664.
20. Wang, E. A Roadmap of Cancer Systems Biology; CRC Press: Boca Raton, FL, USA, 2010.
21. You, L.; Zhang, B.; Tang, Y.J. Application of stable isotope-assisted metabolomics for cell metabolism studies. Metabolites 2014, 4, 142–165.
22. Costello, L.C.; Franklin, R.B. Tumor cell metabolism: The marriage of molecular genetics and proteomics with cellular intermediary metabolism; proceed with caution! Mol. Cancer 2006, 5, 59, doi:10.1186/1476-4598-5-59.
23. Raamsdonk, L.M.; Teusink, B.; Broadhurst, D.; Zhang, N.; Hayes, A.; Walsh, M.C.; Berden, J.A.; Brindle, K.M.; Kell, D.B.; Rowland, J.J. et al. A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat. Biotechnol. 2001, 19, 45–50.
24. Artati, A.; Prehn, C.; Möller, G.; Adamski, J. Assay tools for metabolomics. In Genetics Meets Metabolomics; Suhre, K., Ed. Springer International Publishing AG: Gewerbestrasse, Switzerland, 2012.
25. Wolfe, R.R.; Chinkes, D.L. Isotope Tracers in Metabolic Research: Principles and Practice of Kinetic Analysis. 2nd ed.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2005.
26. Kreeger, P.K.; Lauffenburger, D.A. Cancer systems biology: A network modeling perspective. Carcinogenesis 2010, 31, 2–8.
27. Tan, A.S.; Baty, J.W.; Berridge, M.V. The role of mitochondrial electron transport in tumorigenesis and metastasis. Biochim. Biophys. Acta 2014, 1840, 1454–1463.
28. Benjamin, D.I.; Cravatt, B.F.; Nomura, D.K. Global profiling strategies for mapping dysregulated metabolic pathways in cancer. Cell Metab. 2012, 16, 565–577.
29. Nagrath, D.; Caneba, C.; Karedath, T.; Bellance, N. Metabolomics for mitochondrial and cancer studies. Biochim. Biophys. Acta 2011, 1807, 650–663.
30. Lewis, N.E.; Abdel-Haleem, A.M. The evolution of genome-scale models of cancer metabolism. Front. Physiol. 2013, 4, 237, doi:10.3389/fphys.2013.00237.
31. Khazaei, T.; McGuigan, A.; Mahadevan, R. Ensemble modeling of cancer metabolism. Front. Physiol. 2012, 3, 135, doi:10.3389/fphys.2012.00135.
32. Guhathakurta, D.; Sheikh, N.A.; Meagher, T.C.; Letarte, S.; Trager, J.B. Applications of systems biology in cancer immunotherapy: From target discovery to biomarkers of clinical outcome. Expert Rev. Clin. Pharmacol. 2013, 6, 387–401.
33. Coller, H.A. Is cancer a metabolic disease? Am. J. Pathol. 2014, 184, 4–17.
34. Kim, J.W.; Dang, C.V. Cancer’s molecular sweet tooth and the warburg effect. Cancer Res. 2006, 66, 8927–8930.
35. Prasasya, R.D.; Tian, D.; Kregger, P.K. Analysis of cancer signaling networks by systems biology to develop therapies. Semin. Cancer Biol. 2011, 21, 200–206.
36. Munoz-Pinedo, C.; El Mjiyad, N.; Ricci, J.E. Cancer metabolism: Current perspectives and future directions. Cell Death Dis. 2012, 3, e248, doi:10.1038/cddis.2011.123.
37. Cantor, J.R.; Sabatini, D.M. Cancer cell metabolism: One hallmark, many faces. Cancer Discov. 2012, 2, 881–898.
38. Levitzki, A.; Klein, S. Signal transduction therapy of cancer. Mol. Asp. Med. 2010, 31, 287–329.
39. Shaw, R.J.; Cantley, L.C. Ras, pi(3)k and mtor signalling controls tumour cell growth. Nature 2006, 441, 424–430.
40. Yuan, T.L.; Cantley, L.C. Pi3k pathway alterations in cancer: Variations on a theme. Oncogene 2008, 27, 5497–5510.
41. Vivanco, I.; Sawyers, C.L. The phosphatidylinositol 3-kinase akt pathway in human cancer. Nat. Rev. Cancer 2002, 2, 489–501.
42. Galluzzi, L.; Kepp, O.; Vander Heiden, M.G.; Kroemer, G. Metabolic targets for cancer therapy. Nat. Rev. Drug Discov. 2013, 12, 829–846.
43. Gunther, U.L.; Chong, M.G.; Volpari, T.; Koczula, K.M.; Atkins, K.; Bunce, C.M.; Khanim, F.L. Metabolic fluxes in cancer metabolism. In Tumor Cell Metabolism; Mazurek, S., Shoshan, M., Eds.; Springer-Verlag Wien: Birmingham, UK, 2015.
44. Jones, N.P.; Schulze, A. Targeting cancer metabolism—Aiming at a tumour’s sweet-spot. Drug Discov. Today 2012, 17, 232–241.
45. Bos, J.L. Ras oncogenes in human cancer: A review. Cancer Res. 1989, 49, 4682–4689.
46. Gaglio, D.; Metallo, C.M.; Gameiro, P.A.; Hiller, K.; Danna, L.S.; Balestrieri, C.; Alberghina, L.; Stephanopoulos, G.; Chiaradonna, F. Oncogenic k-ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol. Syst. Biol. 2011, 7, 523, doi:10.1038/msb.2011.56.
47. Mihaylova, M.M.; Shaw, R.J. The ampk signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 2011, 13, 1016–1023.
48. Shaw, R.J.; Kosmatka, M.; Bardeesy, N.; Hurley, R.L.; Witters, L.A.; DePinho, R.A.; Cantley, L.C. The tumor suppressor lkb1 kinase directly activates amp-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad Sci. USA 2004, 101, 3329–3335.
49. Zhou, S.; Huang, C.; Wei, Y. The metabolic switch and its regulation in cancer cells. Sci. China Life Sci. 2010, 53, 942–958.
50. Soga, T. Cancer metabolism: Key players in metabolic reprogramming. Cancer Sci. 2013, 104, 275–281.
51. Semenza, G.L. Hif-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J. Clin. Investig. 2013, 123, 3664–3671.
52. Wiesener, M.S.; Jurgensen, J.S.; Rosenberger, C.; Scholze, C.K.; Horstrup, J.H.; Warnecke, C.; Mandriota, S.; Bechmann, I.; Frei, U.A.; Pugh, C.W. et al. Widespread hypoxia-inducible expression of hif-2alpha in distinct cell populations of different organs. FASEB J. 2003, 17, 271–273.
53. Gameiro, P.A.; Yang, J.; Metelo, A.M.; Perez-Carro, R.; Baker, R.; Wang, Z.; Arreola, A.; Rathmell, W.K.; Olumi, A.; Lopez-Larrubia, P. et al. In vivo hif-mediated reductive carboxylation is regulated by citrate levels and sensitizes vhl-deficient cells to glutamine deprivation. Cell Metab. 2013, 17, 372–385.
54. Finkel, T. Signal transduction by reactive oxygen species. J. Cell Biol. 2011, 194, 7–15.
55. Dang, C.V. Links between metabolism and cancer. Genes Dev. 2012, 26, 877–890.
56. Choudhari, S.K.; Chaudhary, M.; Bagde, S.; Gadbail, A.R.; Joshi, V. Nitric oxide and cancer: A review. World J. Surg. Oncol. 2013, 11, 118, doi:10.1186/1477-7819-11-118.
57. Anastasiou, D.; Poulogiannis, G.; Asara, J.M.; Boxer, M.B.; Jiang, J.K.; Shen, M.; Bellinger, G.; Sasaki, A.T.; Locasale, J.W.; Auld, D.S. et al. Inhibition of pyruvate kinase m2 by reactive oxygen species contributes to cellular antioxidant responses. Science 2011, 334, 1278–1283.
58. Osthus, R.C.; Shim, H.; Kim, S.; Li, Q.; Reddy, R.; Mukherjee, M.; Xu, Y.; Wonsey, D.; Lee, L.A.; Dang, C.V. Deregulation of glucose transporter 1 and glycolytic gene expression by c-myc. J. Biol. Chem. 2000, 275, 21797–21800.
59. Sermeus, A.; Michiels, C. Reciprocal influence of the p53 and the hypoxic pathways. Cell Death Dis. 2011, 2, e164, doi:10.1038/cddis.2011.48.
60. Cascante, M.; Benito, A.; Zanuy, M.; Vizan, P.; Marin, S.; de Atauri, P. Metabolic network adaptations in cancer as targets for novel therapies. Biochem. Soc. Trans. 2010, 38, 1302–1306.
61. Lunt, S.Y.; Vander Heiden, M.G. Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 2011, 27, 441–464.
62. Fantin, V.R.; St-Pierre, J.; Leder, P. Attenuation of ldh-a expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006, 9, 425–434.
63. Le, A.; Cooper, C.R.; Gouw, A.M.; Dinavahi, R.; Maitra, A.; Deck, L.M.; Royer, R.E.; Vander Jagt, D.L.; Semenza, G.L.; Dang, C.V. Inhibition of lactate dehydrogenase a induces oxidative stress and inhibits tumor progression. Proc. Natl. Acad. Sci. USA 2010, 107, 2037–2042.
64. Batra, S.; Adekola, K.U.; Rosen, S.T.; Shanmugam, M. Cancer metabolism as a therapeutic target. Oncology 2013, 27, 460–467.
65. Zhao, Y.; Butler, E.B.; Tan, M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013, 4, e532, doi:10.1038/cddis.2013.60.
66. Hulleman, E.; Kazemier, K.M.; Holleman, A.; VanderWeele, D.J.; Rudin, C.M.; Broekhuis, M.J.; Evans, W.E.; Pieters, R.; Den Boer, M.L. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood 2009, 113, 2014–2021.
67. Yan, H.; Parsons, D.W.; Jin, G.; McLendon, R.; Rasheed, B.A.; Yuan, W.; Kos, I.; Batinic-Haberle, I.; Jones, S.; Riggins, G.J. et al. Idh1 and idh2 mutations in gliomas. N. Engl. J. Med. 2009, 360, 765–773.
68. McBrayer, S.K.; Cheng, J.C.; Singhal, S.; Krett, N.L.; Rosen, S.T.; Shanmugam, M. Multiple myeloma exhibits novel dependence on glut4, glut8, and glut11: Implications for glucose transporter-directed therapy. Blood 2012, 119, 4686–4697.
69. Guo, W.; Zhang, Y.; Chen, T.; Wang, Y.; Xue, J.; Zhang, Y.; Xiao, W.; Mo, X.; Lu, Y. Efficacy of rnai targeting of pyruvate kinase m2 combined with cisplatin in a lung cancer model. J. Cancer Res. Clin. Oncol. 2011, 137, 65–72.
70. Vijayakumar, S.N.; Sethuraman, S.; Krishnan, U.M. Metabolic pathways in cancers: Key targets and implications in cancer therapy. RSC Adv. 2015, 5, 41751–41762.
71. Bustamante, E.; Pedersen, P.L. High aerobic glycolysis of rat hepatoma cells in culture: Role of mitochondrial hexokinase. Proc. Natl. Acad. Sci. USA 1977, 74, 3735–3739.
72. Bustamante, E.; Morris, H.P.; Pedersen, P.L. Energy metabolism of tumor cells. Requirement for a form of hexokinase with a propensity for mitochondrial binding. J. Biol. Chem. 1981, 256, 8699–8704.
73. Cheng, Y.; Diao, D.; Zhang, H.; Guo, Q.; Wu, X.; Song, Y.; Dang, C. High glucose-induced resistance to 5-fluorouracil in pancreatic cancer cells alleviated by 2-deoxy-d-glucose. Biomed. Rep. 2014, 2, 188–192.
74. Pilkis, S.J.; Claus, T.H. Hepatic gluconeogenesis/glycolysis: Regulation and structure/function relationships of substrate cycle enzymes. Annu. Rev. Nutr. 1991, 11, 465–515.
75. Staal, G.E.; Kalff, A.; Heesbeen, E.C.; van Veelen, C.W.; Rijksen, G. Subunit composition, regulatory properties, and phosphorylation of phosphofructokinase from human gliomas. Cancer Res. 1987, 47, 5047–5051.
76. Ashizawa, K.; Willingham, M.C.; Liang, C.M.; Cheng, S.Y. In vivo regulation of monomer-tetramer conversion of pyruvate kinase subtype m2 by glucose is mediated via fructose 1,6-bisphosphate. J. Biol. Chem. 1991, 266, 16842–16846.
77. Griffin, J.L.; Shockcor, J.P. Metabolic profiles of cancer cells. Nat. Rev. Cancer 2004, 4, 551–561.
78. Riganti, C.; Gazzano, E.; Polimeni, M.; Aldieri, E.; Ghigo, D. The pentose phosphate pathway: An antioxidant defense and a crossroad in tumor cell fate. Free Radic. Biol. Med. 2012, 53, 421–436.
79. DeBerardinis, R.J.; Mancuso, A.; Daikhin, E.; Nissim, I.; Yudkoff, M.; Wehrli, S.; Thompson, C.B. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl. Acad. Sci. USA 2007, 104, 19345–19350.
80. Dang, L.; White, D.W.; Gross, S.; Bennett, B.D.; Bittinger, M.A.; Driggers, E.M.; Fantin, V.R.; Jang, H.G.; Jin, S.; Keenan, M.C. et al. Cancer-associated idh1 mutations produce 2-hydroxyglutarate. Nature 2009, 462, 739–744.
81. Mardis, E.R.; Ding, L.; Dooling, D.J.; Larson, D.E.; McLellan, M.D.; Chen, K.; Koboldt, D.C.; Fulton, R.S.; Delehaunty, K.D.; McGrath, S.D. et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 2009, 361, 1058–1066.
82. Parsons, D.W.; Jones, S.; Zhang, X.; Lin, J.C.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I.M.; Gallia, G.L. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321, 1807–1812.
83. Reitman, Z.J.; Jin, G.; Karoly, E.D.; Spasojevic, I.; Yang, J.; Kinzler, K.W.; He, Y.; Bigner, D.D.; Vogelstein, B.; Yan, H. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc. Natl. Acad. Sci. USA 2011, 108, 3270–3275.
84. Pollard, P.J.; Briere, J.J.; Alam, N.A.; Barwell, J.; Barclay, E.; Wortham, N.C.; Hunt, T.; Mitchell, M.; Olpin, S.; Moat, S.J. et al. Accumulation of krebs cycle intermediates and over-expression of hif1alpha in tumours which result from germline fh and sdh mutations. Hum. Mol. Genet. 2005, 14, 2231–2239.
85. Nicklin, P.; Bergman, P.; Zhang, B.; Triantafellow, E.; Wang, H.; Nyfeler, B.; Yang, H.; Hild, M.; Kung, C.; Wilson, C. et al. Bidirectional transport of amino acids regulates mtor and autophagy. Cell 2009, 136, 521–534.
86. Locasale, J.W.; Grassian, A.R.; Melman, T.; Lyssiotis, C.A.; Mattaini, K.R.; Bass, A.J.; Heffron, G.; Metallo, C.M.; Muranen, T.; Sharfi, H. et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat. Genet. 2011, 43, 869–874.
87. Tomita, M.; Kami, K. Cancer. Systems biology, metabolomics, and cancer metabolism. Science 2012, 336, 990–991.
88. Menendez, J.A.; Lupu, R.; Colomer, R. Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of her -2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere). Breast Cancer Res. Treat. 2004, 84, 183–195.
89. Types of Chemotherapy Drugs. Available online: http://www.cancer.org/treatment/treatmentsandsideeffects/treatmenttypes/chemotherapy/chemotherapyprinciplesanin-depthdiscussionofthetechniquesanditsroleintreatment/chemotherapy-principles-types-of-chemo-drugs (accessed on 26 August 2015).
90. Bensaad, K.; Harris, A.L. Cancer metabolism as a therapeutic target: Metabolic synthetic lethality. Oncology 2013, 27, 467, 473–474.
91. Wilson, W.R.; Hay, M.P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 2011, 11, 393–410.
92. Chiarini, F.; Grimaldi, C.; Ricci, F.; Tazzari, P.L.; Evangelisti, C.; Ognibene, A.; Battistelli, M.; Falcieri, E.; Melchionda, F.; Pession, A. et al. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor nvp-bez235 against t-cell acute lymphoblastic leukemia. Cancer Res. 2010, 70, 8097–8107.
93. Michelakis, E.D.; Webster, L.; Mackey, J.R. Dichloroacetate (dca) as a potential metabolic-targeting therapy for cancer. Br. J. Cancer 2008, 99, 989–994.
94. Yangzom, D.; Bhutia, E.B.; Prasad, P.D.; Ganapathy, V. The amino acid transporter slc6a14 in cancer and its potential use in chemotherapy. Asian J. Pharm. Sci. 2014, 9, 293–303.
95. Rahman, M. Pentose phosphate pathway in disease and therapy. Adv. Mater. Res. 2014, 995, 1–27.